Yesterday, the SVP & Chief Scientific Officer of Nektar Therapeutics (NKTR), Stephen Doberstein, bought shares of NKTR for $259.2K.
Following this transaction Stephen Doberstein’s holding in the company was increased by 16.19% to a total of $1.92 million. Following Stephen Doberstein’s last NKTR Buy transaction on February 17, 2017, the stock climbed by 4.8%.
See today’s analyst top recommended stocks >>
The company has a one-year high of $66.95 and a one-year low of $16.56.
Six different firms, including BMO Capital and BTIG, currently also have a Buy rating on the stock.
The insider sentiment on Nektar Therapeutics has been positive according to 51 insider trades in the past three months. This sentiment is higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nektar Therapeutics is a biopharmaceutical company, which engages in applying technology platforms to develop novel drug candidates. The company focuses on the therapies for cancer, autoimmune disease, and chronic pain. It operates through the United States and Europe geographical segments.
